Amp Volatility Score
Catalyst Info & Data Links
TITLE: KX2-361 for Glioblastoma Phase 1
NCT02326441: Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
WHAT IS THE NEXT CATALYST EVENT?
Phase 1 data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
01-2020 Corporate Presentation (slide 30)
12-16-2019 Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao
Ciesielski MJ, Bu Y, Munich SA, Teegarden P, Smolinski MP, Clements JL, Lau JYN, Hangauer DG, Fenstermaker RA. KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma. J Neurooncol. 2018 Dec;140(3):519-527. doi: 10.1007/s11060-018-2992-4. Epub 2018 Sep 20. PMID: 30238350.
MECHANISM OF ACTION
The Src Kinase inhibition platform refers to novel small molecule compounds that have differentiated mechanisms of actions (MOAs) including: (1) the inhibition of the activity of Src Kinase and (2) the inhibition of tubulin polymerization. We believe the combination of the two mechanisms of action provides a broader range of anticancer activity compared to either mechanism of action alone. Our three key clinical product candidates in this platform are tirbanibulin (formerly KX2-391 or KX-01) ointment for actinic keratosis, pre-cancerous lesions and psoriasis; tirbanibulin oral for solid and liquid tumors, and KX2-361 (formerly KX-02) oral for glioblastoma multiforme (GBM).
Updated by MV
#glioblastoma #ATNX #KX2361 #cancer
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post